Global Custom Market Research Reports Provider Company

phone

Pruritus - Pipeline Review, H1 2018

  • Published Date: 27 Feb 2018
  • Number of Pages: 134
  • Category: Pharmaceuticals
  • Country: Global

Pruritus - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H1 2018, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Pruritus - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 6, 15, 3, 1 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Publisher Name : Global Markets Direct


Introduction
Global Markets Direct Report Coverage
Pruritus - Overview
Pruritus - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pruritus - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pruritus - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Allergan Plc
Amgen Inc
Amorepacific Corp
Asana BioSciences LLC
Cara Therapeutics Inc
Celgene Corp
Chugai Pharmaceutical Co Ltd
ELORAC Inc
GlaxoSmithKline Plc
Hydra Biosciences Inc
Japan Tobacco Inc
NeuroCycle Therapeutics GmbH
Patagonia Pharmaceuticals LLC
Patara Pharma Inc
RDD Pharma Ltd
Sanwa Kagaku Kenkyusho Co Ltd
Sienna Biopharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Teikoku Pharma USA Inc
Tesaro Inc
Tioga Pharmaceuticals Inc
Toray Industries Inc
Vanda Pharmaceuticals Inc
Pruritus - Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-8379 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apremilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
asimadoline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASN-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bepotastine besilate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cromolyn sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
difelikefalin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTS-661 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalbuphine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalfurafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCT-10004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPK-88002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orvepitant maleate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PATN-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Target TRPV1 for Pain and Itch - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PR-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDD-1609 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
serlopitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-1405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize KOR1 for Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TRPV3 for Pain,Pruritus and Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNA-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNA-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPU-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tradipitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VVZ-149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pruritus - Dormant Projects
Pruritus - Discontinued Products
Pruritus - Product Development Milestones
Featured News & Press Releases
Feb 14, 2018: Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125
Jan 31, 2018: Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus
Nov 21, 2017: Menlo Therapeutics Begins Phase 2 Clinical Trial for Pruritus Associated with Psoriasis
Oct 31, 2017: Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting
Oct 24, 2017: Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
Oct 17, 2017: Cara Therapeutics Announces Participation in ANESTHESIOLOGY 2017
Oct 17, 2017: Menlo Therapeutics Expands its Management Team
Oct 16, 2017: Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
Oct 16, 2017: Cara Therapeutics to Present Data at Kidney Week 2017
Oct 03, 2017: Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting 2017
Sep 22, 2017: Toray Receives Japanese Approval for an Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5µg and REMITCH OD Tablets 2.5µg
Sep 18, 2017: Serlopitant Pruritus Reduction Results from Two Phase 2 Studies Presented at the 26th European Academy of Dermatology and Venereology
Sep 13, 2017: Vandas Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis
Aug 01, 2017: Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer
Jun 23, 2017: Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
 



List Of Tables

List of Tables
Number of Products under Development for Pruritus, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pruritus - Pipeline by Albireo Pharma Inc, H1 2018
Pruritus - Pipeline by Allergan Plc, H1 2018
Pruritus - Pipeline by Amgen Inc, H1 2018
Pruritus - Pipeline by Amorepacific Corp, H1 2018
Pruritus - Pipeline by Asana BioSciences LLC, H1 2018
Pruritus - Pipeline by Cara Therapeutics Inc, H1 2018
Pruritus - Pipeline by Celgene Corp, H1 2018
Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Pruritus - Pipeline by ELORAC Inc, H1 2018
Pruritus - Pipeline by GlaxoSmithKline Plc, H1 2018
Pruritus - Pipeline by Hydra Biosciences Inc, H1 2018
Pruritus - Pipeline by Japan Tobacco Inc, H1 2018
Pruritus - Pipeline by NeuroCycle Therapeutics GmbH, H1 2018
Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, H1 2018
Pruritus - Pipeline by Patara Pharma Inc, H1 2018
Pruritus - Pipeline by RDD Pharma Ltd, H1 2018
Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2018
Pruritus - Pipeline by Sienna Biopharmaceuticals Inc, H1 2018
Pruritus - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018
Pruritus - Pipeline by Teikoku Pharma USA Inc, H1 2018
Pruritus - Pipeline by Tesaro Inc, H1 2018
Pruritus - Pipeline by Tioga Pharmaceuticals Inc, H1 2018
Pruritus - Pipeline by Toray Industries Inc, H1 2018
Pruritus - Pipeline by Vanda Pharmaceuticals Inc, H1 2018
Pruritus - Dormant Projects, H1 2018
Pruritus - Dormant Projects, H1 2018 (Contd..1), H1 2018
Pruritus - Discontinued Products, H1 2018



List Of Figures

List of Figures
Number of Products under Development for Pruritus, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018



PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2018 Edition The motivation for pharma companies outsourcing their manufacturing is often to do with

View Report

2018 Banking Competitor Profile: Barclays Barclays is one of the largest banks in the UK, and is a leading provider of all the main banking products. Mortgages are a particular strength

View Report

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2018 in Pharmaceuticals GlobalDatas Partnerships, Licensing, Investments and M&A Deals and Trends for April 2018 in Pharmaceuticals , report is an essential

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports